Albertans across the province can join the movement on Giving Tuesday and throughout the holiday season by visiting AlbertaCancer.ca/MoreTime to give the gift of time. Thanks to the generosity of ...
Comanche Biopharma today announced the strengthening of its leadership team with the appointments of Richard Colvin, MD, PhD, as Global Head of Research and Development (R&D), and John McHutchison, AO ...
The Company recently announced that it would advance development of TZLS-501, a dual-action IL-6R monoclonal antibody targeting both membrane-bound and soluble forms of IL-6R. This decision was based ...
Tacalyx, a privately held biotech company focused on developing novel TACA (Tumour Associated Carbohydrate Antigens) cancer therapies, announces the appointment of Jean Engela as Chief Executive ...
Additionally, pharmacokinetic analyses demonstrated no reduction in cisplatin exposure, and there was no evidence of adverse interaction or attenuation of antitumor activity. The overall tumor ...
Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with ...
“These two facilities were perfect additions to our recent growth in Colorado,” said Barry Port, Ensign’s Chief Executive Officer. “Colorado is a fantastic state for us, and we expect these facilities ...
Christie Jones, market leader for Bandera Healthcare LLC, Ensign’s Arizona-based subsidiary, added, “We are excited to work together with the outstanding care team at the facility and combine their ...
In another transaction on the same day, Ensign announced that it acquired the operations of “ Santa Rosa Care Center”, a 144-bed skilled nursing facility located in Tucson, Arizona. The facility is ...
Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the ...
Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regulatory approval. The foundation for her expert drug development perspectives ...
Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback